Media coverage about Tandem Diabetes Care (NASDAQ:TNDM) has been trending somewhat positive on Tuesday, Accern Sentiment reports. The research group identifies negative and positive media coverage by monitoring more than 20 million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Tandem Diabetes Care earned a media sentiment score of 0.06 on Accern’s scale. Accern also gave media coverage about the medical device company an impact score of 47.1123255353696 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the immediate future.

Here are some of the news headlines that may have impacted Accern’s analysis:

Several research firms recently issued reports on TNDM. Zacks Investment Research raised Tandem Diabetes Care from a “hold” rating to a “buy” rating and set a $7.50 target price on the stock in a research note on Thursday, September 28th. Wedbush reissued an “outperform” rating and set a $17.00 target price (down previously from $50.00) on shares of Tandem Diabetes Care in a research note on Tuesday, October 10th. Finally, Piper Jaffray Companies reissued a “hold” rating and set a $15.00 target price on shares of Tandem Diabetes Care in a research note on Friday, October 6th. Four analysts have rated the stock with a hold rating and two have given a buy rating to the stock. The stock has an average rating of “Hold” and an average target price of $12.95.

Tandem Diabetes Care (NASDAQ:TNDM) traded up $0.03 during mid-day trading on Tuesday, reaching $2.32. The company’s stock had a trading volume of 347,648 shares, compared to its average volume of 815,998. The company has a current ratio of 1.90, a quick ratio of 0.88 and a debt-to-equity ratio of -2.70. Tandem Diabetes Care has a 52 week low of $2.15 and a 52 week high of $32.50.

Tandem Diabetes Care (NASDAQ:TNDM) last posted its quarterly earnings results on Thursday, October 26th. The medical device company reported ($3.09) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($3.74) by $0.65. The company had revenue of $27.00 million for the quarter, compared to analyst estimates of $25.92 million. Tandem Diabetes Care had a negative return on equity of 1,177.11% and a negative net margin of 79.45%. Tandem Diabetes Care’s revenue for the quarter was up 119.7% compared to the same quarter last year. During the same quarter last year, the company earned ($0.97) EPS. equities analysts forecast that Tandem Diabetes Care will post -15.71 EPS for the current fiscal year.

In related news, CEO Kim D. Blickenstaff purchased 285,700 shares of Tandem Diabetes Care stock in a transaction on Friday, October 13th. The shares were bought at an average price of $3.50 per share, with a total value of $999,950.00. The transaction was disclosed in a document filed with the SEC, which is available through this link. 20.90% of the stock is owned by company insiders.

ILLEGAL ACTIVITY NOTICE: “Tandem Diabetes Care (TNDM) Earns Daily Media Impact Rating of 0.06” was originally reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this report on another publication, it was copied illegally and republished in violation of United States and international copyright and trademark legislation. The original version of this report can be read at

About Tandem Diabetes Care

Tandem Diabetes Care, Inc is a medical device company. The Company is engaged in designing, developing and commercializing products for people with insulin-dependent diabetes. The Company manufactures and sells three insulin pump products, which include t:slim Insulin Delivery System (t:slim), t:flex Insulin Delivery System (t:flex) and t:slim G4 Insulin Delivery System (t:slim G4).

Insider Buying and Selling by Quarter for Tandem Diabetes Care (NASDAQ:TNDM)

Receive News & Stock Ratings for Tandem Diabetes Care Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tandem Diabetes Care Inc. and related stocks with our FREE daily email newsletter.